Thai oil firm PTT expands pharma business with US$475m Alvogen deal
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
[BANGKOK] Thailand's state-owned oil firm PTT is set to expand further into pharmaceuticals as part of a consortium acquiring a unit of drugmaker Alvogen, the parent of Taiwan's Lotus Pharmaceutical, PTT said on Friday.
A consortium of PTT and Icelandic investment fund Aztiq have agreed a US$475 million purchase of Alvogen Emerging Markets Holdings, which holds a 57.48 per cent stake in Lotus, according to Refinitiv Eikon.
The Alvogen unit also owns Adalvo, a business-to-business pharmaceutical firm based in Malta.
PTT said it will have a 37 per cent indirect shareholding in Lotus - which makes drugs to treat cancer, cardiovascular disease and mental diseases - when the deal closes in the first quarter of 2022 and 60 per cent of Adalvo.
In April, PTT bought 6.6 per cent of Lotus for US$50 million.
The move is part of the oil and gas firm's strategy to diversify its business away from fossil fuels. It has previously announced plans in electric vehicle production and the expansion of its coffee shop franchise, Café Amazon, in Asia.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
Aztiq is led by Robert Wessman, who is also chairman of Lotus Pharmaceutical and Alvogen.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
